Terms: = Leukemia AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Clinical Outcome
11 results:
1. Influence of Immunogenetic Biomarkers in the clinical outcome of HTLV-1 Infected Persons.
Vallinoto ACR; Cayres-Vallinoto I; Freitas Queiroz MA; Ishak MOG; Ishak R
Viruses; 2019 Oct; 11(11):. PubMed ID: 31652745
[TBL] [Abstract] [Full Text] [Related]
2. Association of promoter polymorphisms of fas -fasL genes with development of Chronic Myeloid leukemia.
Edathara PM; Gorre M; Kagita S; Vuree S; Cingeetham A; Nanchari SR; Meka PB; Annamaneni S; Digumarthi RR; Satti V
Tumour Biol; 2016 Apr; 37(4):5475-84. PubMed ID: 26563376
[TBL] [Abstract] [Full Text] [Related]
3. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia.
Scielzo C; Apollonio B; Scarfò L; Janus A; Muzio M; Ten Hacken E; Ghia P; Caligaris-Cappio F
Leukemia; 2011 Nov; 25(11):1760-7. PubMed ID: 21709686
[TBL] [Abstract] [Full Text] [Related]
4. fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia.
Farre L; Bittencourt AL; Silva-Santos G; Almeida A; Silva AC; Decanine D; Soares GM; Alcantara LC; Van Dooren S; Galvão-Castro B; Vandamme AM; Van Weyenbergh J
J Leukoc Biol; 2008 Jan; 83(1):220-2. PubMed ID: 17962369
[TBL] [Abstract] [Full Text] [Related]
5. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia.
Zalewska-Szewczyk B; Andrzejewski W; Młynarski W; Jedrychowska-Dańska K; Witas H; Bodalski J
Leuk Lymphoma; 2007 May; 48(5):931-6. PubMed ID: 17487737
[TBL] [Abstract] [Full Text] [Related]
6. fas, fas-associated death domain-like interleukin 1beta-converting enzyme-like inhibitory protein, and apoptotic features of elderly acute myeloid leukemia based on response to induction chemotherapy.
Kim HJ; Park BH; Choi Y; Min WS; Lee JW; Kim CC
Int J Hematol; 2005 Nov; 82(4):327-32. PubMed ID: 16298825
[TBL] [Abstract] [Full Text] [Related]
7. c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome.
Valnet-Rabier MB; Challier B; Thiebault S; Angonin R; Margueritte G; Mougin C; Kantelip B; Deconinck E; Cahn JY; Fest T
Br J Haematol; 2005 Mar; 128(6):767-73. PubMed ID: 15755279
[TBL] [Abstract] [Full Text] [Related]
8. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.
Tourneur L; Delluc S; Lévy V; Valensi F; Radford-Weiss I; Legrand O; Vargaftig J; Boix C; Macintyre EA; Varet B; Chiocchia G; Buzyn A
Cancer Res; 2004 Nov; 64(21):8101-8. PubMed ID: 15520222
[TBL] [Abstract] [Full Text] [Related]
9. Aberrant processing of fas transcripts in adult T-cell leukemia: a possible role in tumor cell survival.
Tawara M; Maeda T; Yamada Y; Harasawa H; Tsuruda K; Sugahara K; Moriuchi R; Tomonaga M; Kamihira S
Cancer Lett; 2003 Apr; 193(2):235-42. PubMed ID: 12706882
[TBL] [Abstract] [Full Text] [Related]
10. clinical significance of CD38 expression in chronic lymphocytic leukemia.
Del Poeta G; Maurillo L; Venditti A; Buccisano F; Epiceno AM; Capelli G; Tamburini A; Suppo G; Battaglia A; Del Principe MI; Del Moro B; Masi M; Amadori S
Blood; 2001 Nov; 98(9):2633-9. PubMed ID: 11675331
[TBL] [Abstract] [Full Text] [Related]
11. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer.
Backus HH; van Riel JM; van Groeningen CJ; Vos W; Dukers DF; Bloemena E; Wouters D; Pinedo HM; Peters GJ
Ann Oncol; 2001 Jun; 12(6):779-85. PubMed ID: 11484952
[TBL] [Abstract] [Full Text] [Related]
